{"paper_id":"543c98f0-6241-486f-a4ef-f46a34e6c5cf","body_text":"research article\nNo benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting\n2011\nObjective. About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable.\nType\nresearch article\nWeb of Science ID\nWOS:000291240700012\nAuthor(s)\nJacob, Francis\nMeier, Mara\nCaduff, Rosmarie\nPochechueva, Tatiana\nHacker, Neville\nFink, Daniel\nHeinzelmann-Schwarz, Viola\nDate Issued\n2011\nPublished in\nVolume\n121\nStart page\n487\nEnd page\n491\nSubjects\nEditorial or Peer reviewed\nREVIEWED\nWritten at\nEPFL\nEPFL units\nAvailable on Infoscience\nDecember 16, 2011\nUse this identifier to reference this record","source_license":"CC0","license_restricted":false}